References
- WHO. Global TB Control 2009. Epidemiology, Strategy, Financing. WHO/HTM/TB/2009.411. WHO, Geneva, Switzerland (2009).
- WHO. Implementing the WHO Stop TB Strategy: A hand book for national TB control programmes. WHO/HTM/TB/2008.401. WHO, Geneva, Switzerland (2008).
- Raviglione MC, Pio A. Evolution of WHO policies for TB control, 1948–2001. Lancet359, 775–780 (2002).
- Garner P, Volmink J. Directly observed treatment for TB. Less faith, more science would be helpful. Br. Med. J.327, 823–824 (2003).
- Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide TB control under the WHO DOTS strategy. Lancet352, 1886–1891 (1998).
- WHO. Community contribution to TB care: practice and policy. WHO/CDS/TB/2003.312. WHO Stop TB Department, Geneva, Switzerland (2003).
- Maher D, Uplekar M, Blanc L, Ravglione M. Treatment of TB: concordance is a key step. Br. Med. J.327, 822–823 (2003).
- WHO. Resolution WHA44.8 of the Forty-forty-fourth World Health Assembly, Geneva, World Health Organization, 1991 (WHA44/1991/REC/1), and Resolution WHA46.36 of the Forty-sixth World Health Assembly, WHO, Geneva, Switzerland (1993).
- Matthys F, Van der Stuyft P, Van Deun A. Universal TB control targets: not so smart. Int. J. Tuberc. Lung Dis.13, 923–924 (2009).
- van der Werf M, Borgdoff MW. Targets for TB control: how confident can we be about the data? Bull. World Health Organ.85, 370–376 (2007).
- Dye C, Bassili A, Bierrenbach AL et al. Measuring TB burden, trends, and impact of control programmes. Lancet Infect. Dis.8, 233–243 (2008).
- WHO. The Global Plan to Stop TB, 2006–2015: actions for life towards a world free of TB. WHO/HTM/STB/2006.35. WHO, Geneva, Switzerland (2006).
- WHO. The Stop TB Strategy: building on and enhancing DOTS to meet the TB-related Millennium Development Goals. WHO/HTM/TB2006.368. WHO, Geneva, Switzerland (2006).
- Dye C, Maher D, Weil D, Espinal M, Raviglione M. Target for global TB control. Int. J. TB Lung Dis.10, 460–462 (2006).
- Donald PR, van Helden PD. The Global burden of TB – combating drug resistance in difficult times. N. Engl. J. Med.360, 2393–2395 (2009).
- Singla R, Sarin R, Khalid UK et al. Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int. J. Tuberc. Lung Dis.13, 976–981 (2009).
- Sotgiu G, Ferrara G, Matteelli A et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur. Respir. J.33, 871–881 (2009).
- Pantoja A, Floyd K, Unnikrishnan KP et al. Economic evaluation of public-private mix for TB care and control, India. Part I. Socio-economic profile and costs among TB patients. Int. J. Tuberc. Lung Dis.13, 698–704 (2009).
- Ling DI, Zwerling AA, Pai M. GenoType MTBDR assasys for the diagnosis of multidrug-resistance TB: a meta-analysis. Eur. Respir. J.32, 1165–1174 (2008).
- TB India 2009. RNTCP Status Report Central TB Division, Govt. of India, New Delhi, India (2009).
- Behera D. TB control in India – a view point. Indian J. Tuberc.54, 63–65 (2007).
- Diacon AH, Pym A, Grobusch M et al. The diarylquinoline AMC207 for multidrug-resistant TB. N. Engl. J. Med.360, 2397–2405 (2009).
Websites
- Ahlburg D. The economic impacts of TB. WHO/CDS/STB/2000.5. WHO, Geneva, Switzerland (2000) www.stoptb.org/conference/ahlburg.pdf
- WHO. Global tuberculosis control and patient care. A ministerial meeting of high M/XDR-TB burden countries. Beijing, China, 1–3 April 2009 www.who.int/tb_beijingmeeting/en/index.html